Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fate Therapeutics (FATE) Income from Continuing Operations (2016 - 2025)

Fate Therapeutics' Income from Continuing Operations history spans 14 years, with the latest figure at 32501000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 43.84% year-over-year to 32501000.0; the TTM value through Dec 2025 reached 136652000.0, up 29.19%, while the annual FY2025 figure was 136652000.0, 29.19% up from the prior year.
  • Income from Continuing Operations reached 32501000.0 in Q4 2025 per FATE's latest filing, down from 32160000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 24898000.0 in Q1 2023 to a low of 84604000.0 in Q3 2022.
  • Average Income from Continuing Operations over 5 years is 51059700.0, with a median of 46750500.0 recorded in 2023.
  • Peak YoY movement for Income from Continuing Operations: tumbled 109.01% in 2021, then surged 66.38% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 69085000.0 in 2021, then grew by 10.92% to 61539000.0 in 2022, then rose by 29.05% to 43661000.0 in 2023, then crashed by 32.55% to 57874000.0 in 2024, then soared by 43.84% to 32501000.0 in 2025.
  • Per Business Quant, the three most recent readings for FATE's Income from Continuing Operations are 32501000.0 (Q4 2025), 32160000.0 (Q3 2025), and 34047000.0 (Q2 2025).